MFG
AZN icon

Menard Financial Group’s AstraZeneca AZN Stock Holding History

Menard Financial Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5
Closed -$655 – 115
2024
Q4 		$655 Buy
+5
New +$700 ﹤0.01% 302

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Menard Financial Group's AZN Position: Q1 2025 in Review

Menard Financial Group sold out of AstraZeneca (AZN) in Q1 2025, closing a stake of 5 shares — an estimated $655 sold.

Menard Financial Group first reported a position in AZN in Q4 2024 and held it in 1 quarter. The position peaked at $655 in Q4 2024. 1,249 funds tracked by Wall St. Rank hold AZN as of Q1 2025.

  • Menard Financial Group reported no remaining AstraZeneca position as of Q1 2025 after selling out during the quarter.
  • Menard Financial Group sold 5 AstraZeneca shares in Q1 2025, an estimated $655.
  • Menard Financial Group first reported a position in AstraZeneca in Q4 2024 and held it in 1 quarter.
  • Menard Financial Group's AstraZeneca position peaked at $655 in Q4 2024.
  • 1,249 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2025.

Based on Menard Financial Group's 13F filing for Q1 2025, filed 8 May 2025.